EMA designates uniQure’s gene therapy for hemophilia a priority – Labiotech.eu (blog)
|
EMA designates uniQure's gene therapy for hemophilia a priority
Labiotech.eu (blog) Following a Breakthrough Designation from the FDA earlier this year, the Dutch biotech has scored the European equivalent for AMT-060. Since its claim to fame, Glybera, fell from grace to become a commercial failure, uniQure has been on the rebound. |
